Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
Following the cancellation of the subsidiary merger, Alteogen issued this corrective filing to formally cancel its previously announced share acquisition decision (859,018 shares of Altos Biologics valued at KRW 31.17B).
📊 [Key Disclosure Details & Financial Highlights]
- Corrected Filing: Decision on Acquisition of Shares and Investment Certificates of Other Corporations (Original Filing Date: 2024-11-07)
- Reason for Correction: Revocation of share acquisition decision due to the cancellation of the subsidiary merger
- Target Corporation: Altos Biologics Corp. (CEO: Hee Jeong Ji, Main Business: Pharmaceutical R&D, Subsidiary)
- Key Correction Details (Cancellation of Acquisition):
- Number of Shares to Acquire: (Before Correction) 859,018 shares ☞ (After Correction) – (Cancelled)
- Acquisition Amount: (Before Correction) KRW 31.17B ☞ (After Correction) – (Cancelled)
- Total Shares and Ownership Ratio After Acquisition: (Before) Previously projected numbers ☞ (After) – (Cancelled)
- Method, Purpose, and Scheduled Date of Acquisition: All items removed and cancelled
- Financial Summary of Target Corporation (Altos Biologics Corp., Unit: KRW Millions):
- Current Year: Total Assets 63,427 / Total Liabilities 5,562 / Total Equity 57,864 / Capital Stock 3,472 / Revenue – / Net Loss -3,339
- Previous Year: Total Assets 61,862 / Total Liabilities 4,239 / Total Equity 57,622 / Capital Stock 3,445 / Revenue – / Net Loss -2,713
- Year Before Previous: Total Assets 62,206 / Total Liabilities 3,085 / Total Equity 59,121 / Capital Stock 3,445 / Revenue – / Net Loss -2,579
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Verification of Corrected Share Acquisition Filings Following Merger Cancellation
This filing serves as a formal corrective disclosure replacing the details of the previously announced share acquisition with cancelled (-) entries due to the subsidiary merger cancellation. Verifying that the cancellation processing of the previous disclosure entries is finalized in the official disclosure database is important to confirm data integrity. The finalized updates can be verified in the corrected disclosure text on DART and upcoming periodic business reports.
📢 Disclaimer & Source Information
Source: This content was structured and generated based on official submission data from the Financial Supervisory Service’s Data Analysis, Retrieval and Transfer System (DART).
Investment Risk Warning: This content is provided solely for informational and linguistic reference purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest entirely with the investor.
Contact: For inquiries regarding regulatory compliance or copyright requests, please contact ksb220805@gmail.com.
